OncoTherapy Science (4564) AI Stock Analysis

• Market Cap: €8.80B
• Dividend Yield: N/A
• Average Volume (3M): 19.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: 51.20%
• EPS Growth: 44.10%
• Country: JP
• Employees: 54
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.13
• Shares Outstanding: 338,643,700
• 10 Day Avg. Volume: 35,047,100
• 30 Day Avg. Volume: 19,346,543
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €27.49
• Price Target Upside: 5.74% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ¥26.00 ▲(0.00% Upside)

The overall stock score of 43 reflects significant financial challenges, with persistent losses and cash flow issues being the most impactful factors. Technical analysis indicates a lack of strong momentum, and valuation metrics highlight ongoing profitability issues. The absence of earnings call data and corporate events limits further insights.

OncoTherapy Science Business Overview & Revenue Model

Company Description

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.

How the Company Makes Money

OncoTherapy Science generates revenue through various streams, including licensing agreements, research and development collaborations, and potential product sales. The company often partners with pharmaceutical and biotechnology firms to co-develop and commercialize its therapeutic candidates, receiving milestone payments and royalties. Additionally, OncoTherapy Science may secure government and private grants to fund its research initiatives, further supporting its financial sustainability.

OncoTherapy Science Financial Statement Overview

Summary

OncoTherapy Science faces significant financial challenges, with persistent losses and cash flow issues. The income statement reflects a struggling financial performance with negative margins, while the balance sheet shows moderate debt levels but declining equity. Cash flow issues are severe, with negative free and operating cash flows, indicating financial instability.

Income Statement

The company has experienced significant challenges in profitability, with consistently negative net and gross profit margins. Revenue growth is erratic, with fluctuations in revenue suggesting instability. EBIT and EBITDA margins have been consistently negative, indicating operational inefficiencies. Overall, the income statement reflects a struggling financial performance, typical in high-risk biotech ventures.

Balance Sheet

The balance sheet shows a relatively high equity ratio, supported by substantial stockholders' equity compared to total assets. However, the company carries significant liabilities, resulting in a moderate debt-to-equity ratio. The consistent decline in total assets and stockholders' equity over the years indicates potential risk. The company's ability to manage liabilities is crucial, given its negative equity growth trend.

Cash Flow

The cash flow statements reveal persistent negative free cash flow and operating cash flow, which are concerning for future liquidity. The company has relied heavily on financing activities to sustain operations, indicating potential challenges in sustaining cash flows from core operations. There is a lack of positive cash flow generation, which poses a risk to financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	749.75M	750.05M	610.12M	1.13B	1.15B	332.48M
Gross Profit	-12.76M	-12.76M	-177.72M	41.69M	113.91M	19.54M
EBITDA	-539.99M	-811.92M	-1.29B	-1.09B	-2.04B	-1.59B
Net Income	-815.05M	-815.28M	-1.29B	-1.12B	-2.57B	-1.56B
Balance Sheet
Total Assets	1.16B	1.16B	867.27M	1.51B	2.69B	3.37B
Cash, Cash Equivalents and Short-Term Investments	833.88M	833.88M	527.66M	1.12B	1.84B	2.90B
Total Debt	51.07M	51.07M	106.85M	0.00	0.00	0.00
Total Liabilities	426.09M	426.09M	513.61M	656.27M	704.97M	291.28M
Stockholders Equity	729.11M	729.11M	353.67M	855.17M	1.98B	3.08B
Cash Flow
Free Cash Flow	0.00	-815.30M	-1.23B	-800.29M	-2.53B	-1.81B
Operating Cash Flow	0.00	-815.02M	-1.23B	-794.90M	-2.07B	-1.76B
Investing Cash Flow	0.00	-279.00K	-33.35M	-20.32M	-467.93M	-52.23M
Financing Cash Flow	0.00	1.12B	671.37M	95.95M	1.48B	0.00

OncoTherapy Science Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 26.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Negative. The current price of 26 is below the 20-day moving average (MA) of 27.50, below the 50-day MA of 27.88, and below the 200-day MA of 26.20, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 44.21 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4564.

OncoTherapy Science Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4583	48 Neutral	¥9.12B	-8.55	―	―	30.92%	26.00%
4593	46 Neutral	¥64.40B	-9.12	-476.97%	―	-78.54%	10.23%
4564	43 Neutral	€8.80B	―	-96.20%	―	51.20%	44.10%
4588	41 Neutral	¥15.95B	-6.68	-61.22%	―	-9.04%	2.12%
4881	38 Underperform	¥4.26B	-2.50	―	―	965.85%	-42.78%
4598	28 Underperform	¥6.18B	-3.13	―	―	―	20.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%